• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Surgery Classics

The EVAR II trial: Endovascular approach when unfit for open aortic aneurysm repair [Classics Series]

byAndrew Cheung, MD MBA
June 23, 2013
in Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. The EVAR II trial compared endovascular abdominal aortic aneurysm repair with no intervention in patients unsuitable for the open procedure.

2. There were significantly fewer aneurysm-related deaths in the endovascular group, compared to no intervention.

3. The rates of complication and reintervention were similar to the rates observed in EVAR I.

Original Date of Publication: May 20, 2010

The Endovascular Aneurysm Repair (EVAR) trials were randomized controlled trials conducted to explore the safety and efficacy of repairing abdominal aortic aneurysms using endovascular methods. Two trials were conducted simultaneously and published in the same issue of The New England Journal of Medicine.

RELATED REPORTS

The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash

Best endovascular treatment superior to vein bypass for patients with chronic limb ischemia requiring infrapopliteal revascularization

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

Study Rundown: Endovascular aortic aneurysm repair was first introduced in the late 1980s as an alternative for people considered unfit for open surgery.  The purpose of the EVAR II trial was to assess the benefits and risks associated with endovascular aortic aneurysm repair in patients who were unfit for the open procedure. There were no significant differences between the two groups in terms of all-cause mortality, though aneurysm-related mortality was significantly lower in the endovascular repair group. This benefit was largely attributed to the significant reductions observed in the 6 month to 4 year period following the repair procedure. Notably, the graft-related complication and reintervention rates were comparable to those observed in the EVAR I trial.

Please click to read study in NEJM

In-Depth [randomized, controlled study]: The EVAR II trial, originally published in 2010 in NEJM, focused on patients who were physically unsuitable for open abdominal aneurysm repair. The trial was supported by the National Institute for Health Research of the United Kingdom (UK). Patients were eligible for the trial if they were at least 60 years of age and had an abdominal aortic aneurysm with a diameter of at least 5.5 cm on computed tomography. Moreover, eligible patients were unsuitable for open repair, but candidates for endovascular repair. Eligible participants were then randomized to receive either endovascular aneurysm repair or no intervention. Again, the primary outcome was all-cause mortality, while other outcomes were aneurysm-related mortality, graft-related complications, and graft-related reinterventions.

A total of 404 patients were recruited from 33 different hospitals across the UK.  Approximately 86% of the participants were male. With regards to all-cause mortality, there were no significant differences between the two groups at any timepoint following the repair. Notably, there were significantly fewer aneurysm-related deaths in the endovascular group compared to the no intervention group (adjusted HR 0.53; 95% CI 0.32-0.89). This difference was driven by significant reductions in mortality in the 6 month to 4 year period following repair (adjusted HR 0.34; 0.16-0.72). In total, 158 graft-related complications and 66 graft-related interventions were observed during the trial, and these rates were comparable to the rates observed in the EVAR I trial.

By Adrienne Cheung, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: aneurysmaortic aneurysmEndovascularEVAR II
Previous Post

Exercise associated with lower pain ratings

Next Post

Oral glucose tolerance test preferred for pre-diabetes screening in PCOS

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Sound of Music, The Rise of a Promising Alzheimer’s Treatment, Pediatric Liver Transplant, A Heart-shaped Rash

February 20, 2024
CABG associated with decreased mortality compared to stenting in diabetic patients
Cardiology

Best endovascular treatment superior to vein bypass for patients with chronic limb ischemia requiring infrapopliteal revascularization

June 8, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Genetics of Alzheimer’s Disease, the Silent Killer, a Holiday Blizzard and an HIV Vaccine on the Horizon

March 14, 2023
Endovascular repair of ruptured AAAs no better than open repair
Cardiology

Development and validation of a prediction model to estimate ascending aorta diameter in asymptomatic individuals

November 17, 2022
Next Post
Oral glucose tolerance test preferred for pre-diabetes screening in PCOS

Oral glucose tolerance test preferred for pre-diabetes screening in PCOS

Severe maternal childhood abuse associated with autism in offspring

Racial differences noted in Autism care

Early feeding practices modifiable through appropriate education

Neonatal growth significantly correlates with early elementary IQ

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
  • Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
  • Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.